Market Overview

Analyst: Entrectinib's Potential Gives Ignyta's Stock 116% Upside

Share:
Analyst: Entrectinib's Potential Gives Ignyta's Stock 116% Upside

Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2 percent of all lung cancer instances.

The firm's Kevin DeGeeter maintains a Buy rating on Ignyta's stock with a price target boosted from $20.25 to $31.

The revised outlook is based mostly on data that was released at the World Conference on Lung Cancer, DeGeeter explained in a report. The company's therapy, entrectinib, showed an improvement of DOR (duration of response) of 28.6 months, which marks an improvement from 17.2 months at the last update in April 2017. The DOR of 28.6 months also comes in ahead of the current standard of care, crizotinib, at 18.3 months.

Assuming that Ignyta's data is replicated in a full phase 2 study then entrectinib will become the preferred frontline therapy as the superior DOR suggests patients would receive a longer benefit from therapy, DeGreeter said. Accordingly, the analyst revised the company's expected market share in 2022 from 46.5 percent to 56.8 percent and entrectinib revenue is now modeled to be $907 million, up from a prior estimate of $574 million.

Ignyta continues to look for a potential partner for international commercial rights to entrectinib which would give the company a "significant near term catalyst"

Related Links:

6 Biotech Stocks Jefferies Says Are Undervalued

Mid-Morning Market Update: Markets Mostly Higher; Abbott Tops Q3 Views

Latest Ratings for RXDX

DateFirmActionFromTo
Dec 2017DowngradesBuyNeutral
Oct 2017MaintainsOverweight
Jun 2016Initiates Coverage onOverweight

View More Analyst Ratings for RXDX
View the Latest Analyst Ratings

Posted-In: cancer Kevin DeGeeter Ladenburg Thalmann lung cancer Rare DiseasesAnalyst Color Price Target Analyst Ratings Best of Benzinga

 

Related Articles (RXDX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
NKEGuggenheimMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Consumer Reports Withholds Recommendation From Microsoft's Surface Book 2

Cramer Breaks Down 3 Cheap Stocks That Crushed Earnings